Home > Products > CD3 & PD1
> Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (VHH-Fc-VHH)
Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (VHH-Fc-VHH) (CAT#: HCAB-031)
Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (VHH-Fc-VHH, Tetravalent HCAb) is a fusion protein of two diabodies connected together by an Fc region. In a diabody, the two VHHs with short linkers are from anti-CD3 and anti-PD1 antibodies. The VH and VL domains form an inter-chain pairing. The diabody with different specificities is fused to the Fc fragment, which results in 2+2 antigen-binding valency and exerts Fc-mediated functions or just extends the half-life. This BsAb can retarget T cells to tumor cells. It is designed for the research of Esophageal cancer; Hodgkin lymphoma; Renal cell cancer (RCC); Mesothelioma; Head and neck squamous cell cancer (HNSCC); Anal cancer; Gastric cancer; Hepatocellular cancer; Nasopharyngeal cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.
CD3 (Cluster of differentiation 3), originally known as T3, is one of the first groups of human T lymphocyte surface antigens recognized by monoclonal antibodies. It has been reported that antibodies against CD3 could either stimulate T cells to divide or inhibit the progress of effector functions according to the conditions used. It plays an important role in T cell and the CD3 T-cell co-receptor helps to activate the cytotoxic T-Cell and T helper cells. The CD3 molecule is composed of a protein complex and consists of four distinct chains. The complex of mammals contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. All these chains associate with T-cell receptor and the ζ-chain to generate an activation signal in T lymphocytes.
There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (VHH-Fc-VHH) (HCAB-031). Click the button below to contact us or submit your feedback about this product.